Colon Cancer Liver Metastasis: Addition of Antiangiogenesis or EGFR Inhibitors to Chemotherapy

This publication has 49 references indexed in Scilit:

• A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer
  British Journal of Cancer, 2011
• Hallmarks of Cancer: The Next Generation
  Cell, 2011
• Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
  Journal of Clinical Oncology, 2010
• Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial
  British Journal of Cancer, 2010
• Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
  The Lancet Oncology, 2010
• Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial
  British Journal of Cancer, 2009
• Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
  New England Journal of Medicine, 2009
• Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
  New England Journal of Medicine, 2009
• Epidemiology and Management of Liver Metastases From Colorectal Cancer
  Annals of Surgery, 2006
• Tumor Angiogenesis: Therapeutic Implications
  New England Journal of Medicine, 1971